303 related articles for article (PubMed ID: 16240690)
1. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
Scotto G; Palumbo E; Fazio V; Tartaglia A; Saracino A; Angarano G
New Microbiol; 2005 Jul; 28(3):193-7. PubMed ID: 16240690
[TBL] [Abstract][Full Text] [Related]
2. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
3. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
7. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
8. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
9. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
Seto WK; Liu K; Fung J; Wong DK; Yuen JC; Hung IF; Lai CL; Yuen MF
Antivir Ther; 2012; 17(7):1255-62. PubMed ID: 22951420
[TBL] [Abstract][Full Text] [Related]
10. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
14. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
15. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
[TBL] [Abstract][Full Text] [Related]
16. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
17. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
18. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Yang Q; Gong ZJ; Hu DF
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
[TBL] [Abstract][Full Text] [Related]
19. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
